Is Mirvetuximab soravtansine approved by the FDA?

Mirvetuximab soravtansine, marketed under the brand name Elahere, is approved by the FDA for the treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. It is specifically used for patients who no longer respond to platinum-based chemotherapy and have received one to three prior types of chemotherapy. The FDA approved Mirvetuximab soravtansine (Elahere) on November 14, 2022.

Usage: 

Mirvetuximab soravtansine is administered intravenously and is typically given every three weeks as an infusion. The exact number of treatment cycles will be determined by your doctor. It may also be used for other purposes not listed in the medication guide.

Side Effects: 

Patients should be aware of the potential side effects, which can range from mild to serious. Some common side effects include:

• Abnormal lab results
• Nausea, stomach pain, diarrhea, constipation
• Fever, mouth sores, skin sores, sore throat, cough
• Pale skin, tiredness, feeling light-headed or short of breath, cold hands and feet

More serious side effects requiring immediate medical attention include:

• Dry eyes, sensitivity to light, blurred vision, eye pain, or new or worsening vision changes
• Cough, chest pain, trouble breathing, shortness of breath
• Numbness, tingling, or burning pain in your hands or feet

Warnings:

• Inform your doctor if you have a history of vision or eye problems, or liver problems.
• Mirvetuximab soravtansine can harm an unborn baby. Use effective birth control while using this medication and for at least seven months after the last dose. You may need to have a negative pregnancy test before starting this treatment.
• Do not breastfeed while using Mirvetuximab soravtansine and for at least one month after your last dose.
• Avoid wearing contact lenses during the treatment unless advised otherwise by your doctor.

Drug Interactions: 

Mirvetuximab soravtansine can interact with other drugs, potentially altering its effectiveness or increasing the risk of side effects. Some known drug interactions include:

• Nefazodone
• Cancer medicines such as ceritinib, idelalisib, ribociclib, tucatinib
• Antibiotics like clarithromycin, telithromycin
• Antifungal medicines such as itraconazole, ketoconazole, posaconazole, voriconazole
• Antiviral medicines for HIV or hepatitis C including boceprevir, cobicistat, dasabuvir, elvitegravir, indinavir, lopinavir/ritonavir, nelfinavir, ombitasvir, paritaprevir, saquinavir, telaprevir, tipranavir

It is crucial to inform your healthcare provider about all the medications you are currently taking, including over-the-counter drugs and supplements, to avoid harmful interactions.

Conclusion: 

Mirvetuximab soravtansine (Elahere) is FDA approved for treating certain types of cancers in adults who are no longer responding to platinum-based chemotherapy. It is important for patients to be aware of potential side effects and interactions with other medications, and to work closely with their healthcare provider to ensure safe and effective treatment.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!